Protalix BioTherapeutics Inc - Company Profile
Powered by
All the data and insights you need on Protalix BioTherapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Protalix BioTherapeutics Inc Strategy Report
- Understand Protalix BioTherapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Protalix Biotherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. Focus on R&D, flagship product, taliglucerase alfa, and the business performance of revenues from selling goods are the major strengths of the company, even as a increase in debt remains a major cause for concern. The company could benefit from its regulatory approvals, growing incidence of cancer and market potential of cystic fibrosis. However, stiff competition, rapid technological changes, and Government regulations could affect the company's growth.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer